The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China

Not yet recruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

December 30, 2027

Conditions

CLL

Interventions

DRUG

BTK inhibitor

patients with treatment naive or R/R CLL who treatment with BTK inhibitor

All Listed Sponsors

lead

Peking University People's Hospital

OTHER

NCT06557304 - The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China | Biotech Hunter | Biotech Hunter